Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
Journal
Infectious diseases and therapy
Journal Volume
11
Journal Issue
4
Pages
1493
Date Issued
2022-08
Author(s)
Abstract
MVC-COV1901 is a protein subunit COVID-19 vaccine based on the stable prefusion spike protein S-2P adjuvanted with CpG 1018 and aluminum hydroxide. Interim results of a phase 2 clinical trial demonstrated favorable safety profile and immunogenicity and the vaccine has been authorized for use in Taiwan. However, waning antibody levels after immunization and variants of concern (VoC) could negatively impact vaccine-induced neutralization of virus. In this extension to the phase 1 clinical study we investigated a three-dose regimen of MVC-COV1901 for durability of antibody levels and virus neutralization capacity, including neutralization of the Omicron variant.
Subjects
Booster vaccination; COVID-19; MVC-COV1901; SARS-CoV-2; SARS-CoV-2 vaccine
SDGs
Publisher
SPRINGER LONDON LTD
Type
journal article